FDA Centralization Plan Under Review; HHS Aiming For “One Clear Message”
This article was originally published in The Gray Sheet
Executive Summary
Consolidation of HHS public affairs and legislative activities across the department will blunt the political impact of the incoming FDA commissioner, potentially allowing the position to focus on science policy and product review issues